drugset / Trial / NCT06447415

Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial

NCT06447415 ↗

Phase 1 Completed 64 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a multi-center, randomized, double-blind, double-dummy, placebo-controlled, single dose escalation study aimed at evaluating the overall safety, tolerability, and preliminary efficacy of HRS-7450 in patients with acute ischemic stroke.

Timeline

Start
2024-08-06
Primary completion
2025-03-18
Completion
2025-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-7450 Unknown — —

Indications